MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

MDS Virtual Congress 2021

September 17-22, 2021. Virtual Congress. www.mdscongress.org

View by Title View Categories
Jump to:  View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z
  • Gabapentin-induced severe myoclonus in a patient with impaired renal function

    M. Akkari, M. Messelmani, H. Derbali, M. Mansour, A. Riahi, I. Bedoui, J. Zaouali, R. Mrissa (Tunis, Tunisia)

  • Gait Dysfunction in Blepharospasm

    H. Sarva, S. Lons, T. Baumer, C. Klein, H. Jinnah (New York, USA)

  • Gait impairment as predictor of falls in patients with early Parkinson’s disease

    I. Stankovic, V. Markovic, S. Radovanovic, I. Petrovic, N. Dragasevic, M. Svetel, E. Stefanova, V. Kostic (Belgrade, Serbia)

  • Gait Improvement in Pegzilarginase-treated Patients With Arginase 1 Deficiency: A Blinded Kinematic Analysis

    N. Foreman, G. Bubb, E. Bradford (Colleyville, USA)

  • Gait instability and dynamic Balance Characteristics in Behavioral variant Frontotemporal dementia: A cross sectional study.

    V. Ganapathy, S R. S R, S. Bharath (Bengaluru, India)

  • GALLIC ACID AMELIORATES THE NEUROBEHAVIOURAL DEFICITS INDUCED BY BISPHENOL A (BPA) IN WISTAR RATS

    K. Adigun, M. Ehinmowo, A. Adebiyi, O. Adebiyi (Ibadan, Nigeria)

  • GASTROINTESTINAL SYMPTOMS ARE ASSOCIATED WITH LEFT PREDOMINANT DOPAMINE TRANSPORTER BINDING DEFICIT IN PARKINSON´S DISEASE

    K. Murtomäki, T. Mertsalmi, E. Jaakkola, E. Mäkinen, R. Levo, T. Nojonen, M. Eklund, S. Nuuttila, K. Lindholm, E. Pekkonen, J. Joutsa, T. Noponen, T. Ihalainen, V. Kaasinen, F. Scheperjans (Helsinki, Finland)

  • GBA Mutation Accumulates Higher Alpha-Synuclein in Alpha-Synucleinopathies

    T. Eid (London, United Kingdom)

  • GBA variants in a multi-ethnic Parkinson’s disease (PD) cohort in Malaysia

    JL. Lim, K. Lohmann, AH. Tan, YW. Tay, KA. Ibrahim, Z. Abdul Aziz, AS. Mawardi, S. Datuk Puvanarajah, I. Looi, YK. Chia, TT. Lim, P. Bauer, A. Rolfs, C. Klein, A. Ahmad-Annuar, S-Y. Lim (Kuala Lumpur, Malaysia)

  • Gender bias in patients with Parkinson’s disease undergoing subthalamic stimulation

    S. Jost, L. Strobel, A. Rizos, P. Loehrer, K. Ashkan, J. Evans, F. Rosenkranz, M. Barbe, G. Fink, J. Franklin, A. Sauerbier, C. Nimsky, A. Sattari, K. Ray Chaudhuri, A. Antonini, L. Timmermann, P. Martinez-Martin, M. Silverdale, E. Kalbe, V. Visser-Vandewalle, H. Dafsari (Cologne, Germany)

  • Genetic factors associated with dementia in Parkinson’s disease in the Parkinson’s Incidence Cohorts Collaboration (PICC)

    A. Szwedo, I. Dalen, M. Camacho, R. Lawson, D. Bäckström, L. Forsgren, C. Tzoulis, OB. Tysnes, A. Macleod, C. Counsell, C. Williams-Gray, KF. Pedersen, G. Alves, J. Maple-Grødem (Stavanger, Norway)

  • Genetic features and long-term outcome of Korean patients with Huntington’s disease.

    YS. Hwang, SY. Jo, SH. Lee, SJ. Chung (Seoul, Republic of Korea)

  • Genetic hypokinetic rigid syndrome: Clinical phenotypes from infancy to adolescence in a series of Chilean Patients

    D. Munoz, M. Troncoso, V. Naranjo, P. Santander, S. Lara, V. Saez, M. Hidalgo, I. Ruiz (Santiago, Chile)

  • Genotype-Phenotype Correlations in Niemann-Pick Disease Type C

    N. Kresojević, M. Ječmenica Lukić, A. Tomić, I. Petrović, N. Dragašević, M. Svetel, V. Dobričić, M. Janković, I. Novaković, V. Kostić (Belgrade, Serbia)

  • Genotype-phenotype relations for GBA as a Parkinson’s disease risk factor gene: MDSGene Systematic Review

    T. Usnich, M. Rossi, N. Schell, J. Boehm, N. Steffen, S. Petkovic, S. Schaake, R. Alcalay, K. Lohmann, C. Klein (Lübeck, Germany)

  • Genotypic and phenotypic spectrum of PINK-1 associated parkinsonism in 44 mutation carriers from 11 Tunisian families

    G. El Fessi, Z. Saied, F. Nebli, M. Zouari, S. Belal, S. Ben Sassi (Tunis, Tunisia)

  • Global access to Parkinson’s disease treatment

    JLY. Cheong, ZHK. Goh, C. Marras, C. Tanner, M. Kasten, A. Korczyn, L. Chahine, R. Lo, A. Noyce (London, United Kingdom)

  • Glucocerebrosidase activity does not predict Parkinson’s Disease risk or severity

    N. Omer, N. Giladi, T. Gurevich, A. Bar-Shira, M. Gana-Weisz, T. Glinka, O. Goldstein, M. Kestenbaum, J. Cedarbaum, O. Mabrouk, K. Fraser, J. Shrivan, A. Orr-Urtreger, A. Mirelman, A. Thaler (Tel-Aviv, Israel)

  • Gluten-induced ataxia: a misdiagnosed cause of sporadic ataxia. A case report

    R. Zouari, M. Messelmani, M. Mansour, H. Derbali, A. Riahi, I. Bedoui, J. Zaouali, R. Mrissa (Tunis, Tunisia)

  • GNAO1 related movement disorders: 2 longitudinally-followed cases

    CC. Wang, S. Lee (Lebanon, USA)

  • GP2: training the next generation of Parkinson’s disease genetics researchers – wherever they are in the world

    S. Dey, A. Noyce, C. Bale, M. Kuhl, H. Leonard, P. Lewis, S. Stott, S. Adams, A. Martinez-Carrasco, B. Stecher, S. Bandres-Ciga, G. Genetics Program (London, United Kingdom)

  • GPi DBS for refractory dystonia 4 years after STN DBS on a Parkinson’s Disease patient

    B. Meira, A. Santos, C. Reizinho, R. Barbosa, M. Mendonça, P. Bugalho (Lisbon, Portugal)

  • GPi-DBS for KMT2B-associated dystonia: systematic review and meta-analysis

    A. Saini (New Deelhi, India)

  • Gut bacterial tyrosine decarboxylase as a predictive biomarker to identify Parkinson’s disease patients with motor fluctuations requiring frequent levodopa administration

    S. van Kessel, L. Verhagen Metman, G. Sanzo, P. Mcnamara, A. Keshavarzian, S. El Aidy (Groningen, Netherlands)

  • Gut dysbiosis in Parkinson’s disease with motor complications

    K. Takahashi, H. Nishiwaki, M. Ito, K. Iwaoka, K. Yamahara, K. Takahashi, Y. Suzuki, K. Taguchi, Y. Tsuboi, K. Kashihara, M. Hirayama, K. Ohno, T. Maeda (Shiwa, Japan)

  • Gut microbiota and nutritional profiles of Parkinson’s disease patients.

    M. Lubomski, X. Xu, A. Holmes, S. Mueller, J. Yang, C. Sue, R. Davis (St Leonards, Australia)

  • Gut microbiota in patients with Parkinson’s disease (PD) predicts disease progression better than clinical features

    H. Nishiwaki, M. Ito, T. Hamaguchi, T. Maeda, K. Kashihara, Y. Tsuboi, M. Masahisa, M. Hirayama, K. Ohno (Nagoya City, Japan)

  • Gut, nasal and oral dysbiosis in Parkinson’s disease

    S. Jo, W. Kang, YS. Hwang, SH. Lee, SJ. Chung (Seoul, Republic of Korea)

Jump to:  View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley